Provided by Tiger Trade Technology Pte. Ltd.

Generate Biomedicines

13.69
-0.1100-0.80%
Post-market: 13.800.1100+0.80%19:59 EDT
Volume:1.26M
Turnover:17.24M
Market Cap:1.75B
PE:-4.18
High:14.30
Open:13.93
Low:13.30
Close:13.80
52wk High:22.67
52wk Low:11.00
Shares:128.19M
Float Shares:60.29M
Volume Ratio:1.23
T/O Rate:2.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2762
EPS(LYR):-4.9816
ROE:-81.72%
ROA:-34.63%
PB:3.85
PE(LYR):-2.75

Loading ...

Seven new option listings on October 2nd

TIPRANKS
·
Oct 02

Analysts Are Bullish on Top NA Stocks: Generate Biomedicines, Inc. (GENB), Netskope, Inc. (NTSK)

TIPRANKS
·
Oct 02

Generate Biomedicines - Gb-5267 Targets Muc16 Biomarker in over 80% of Ovarian Tumors

THOMSON REUTERS
·
Oct 01

Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ Car T Therapy for Ovarian Cancer

THOMSON REUTERS
·
Oct 01

Generate Biomedicines - Gb-5267 Treatment Designed to Avoid Pre-Infusion Chemotherapy

THOMSON REUTERS
·
Oct 01

Generate Biomedicines Price Target Maintained with a $30.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 09

Generate Biomedicines Management to Present at Upcoming Investor Conferences

Reuters
·
Sep 08

Generate Biomedicines Director Frances Arnold Sells USD 16,002 of Common Shares

Reuters
·
Sep 04

Generate Biomedicines is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 28

U.S. Research Roundup-Dollar General, Palo Alto, Workday

Reuters
·
Aug 28

Small U.S. Stocks Finish Mixed as Abercrombie & Fitch Leads, Generate Biomedicines Lags

Dow Jones
·
Aug 27

Generate Biomedicines falls -16.7%

TIPRANKS
·
Aug 27

Generate Biomedicines Starts Phase 3 Solairia Trials of GB-0895 in Severe Uncontrolled Asthma

Reuters
·
Aug 26

Generate Biomedicines rises 17.7%

TIPRANKS
·
Aug 26

Morgan Stanley Sticks to Its Buy Rating for Generate Biomedicines, Inc. (GENB)

TIPRANKS
·
Aug 17

Generate Biomedicines Shares Fall Following Q2 Financial Results

MT Newswires Live
·
Aug 07

Generate Biomedicines Q2 EPS $(0.52) Beats $(0.57) Estimate, Sales $6.314M Miss $6.625M Estimate

Benzinga Earnings
·
Aug 06

Generate Biomedicines - Q2 Revenue $6.30 Mln

THOMSON REUTERS
·
Aug 06

Generate Biomedicines: Existing Cash, Cash Equivalents, and Marketable Securities Sufficient to Fund Current Operating Plan into H1 2028

THOMSON REUTERS
·
Aug 06

Press Release: Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
Aug 06